These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8492647)

  • 1. Depo-Provera.
    Sharts-Hopko NC
    MCN Am J Matern Child Nurs; 1993; 18(2):128. PubMed ID: 8492647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depo Provera: still controversial.
    Wren LM
    Int Health News; 1988 Feb; 9(2):2-3, 8. PubMed ID: 12179873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception.
    Lei ZW; Wu SC; Garceau RJ; Jiang S; Yang QZ; Wang WL; Vander Meulen TC
    Contraception; 1996 Jun; 53(6):357-61. PubMed ID: 8773423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depot medroxyprogesterone acetate pioneers. A retrospective study at a North Carolina Health Department.
    Potter LS; Dalberth BT; Cañamar R; Betz M
    Contraception; 1997 Nov; 56(5):305-12. PubMed ID: 9437559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of levonorgestrel implants with depo-medroxyprogesterone acetate injections for contraception.
    London RS
    J SOGC; 1993 Oct; 15(8):925-8, 32. PubMed ID: 12318530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh.
    Swenson I; Khan AR; Jahan FA
    Contraception; 1980 Mar; 21(3):207-15. PubMed ID: 6446442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depot medroxyprogesterone. Management of side-effects commonly associated with its contraceptive use.
    Archer B; Irwin D; Jensen K; Johnson ME; Rorie J
    J Nurse Midwifery; 1997; 42(2):104-11. PubMed ID: 9107118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
    Mainwaring R; Hales HA; Stevenson K; Hatasaka HH; Poulson AM; Jones KP; Peterson CM
    Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents.
    Polaneczky M; Liblanc M
    J Adolesc Health; 1998 Aug; 23(2):81-8. PubMed ID: 9714170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Contraception with injectable long-acting preparation depo-provera].
    Prilepskaia VN; Kondrikov NI; Tagieva TT
    Akush Ginekol (Mosk); 1995; (3):7-10. PubMed ID: 7653732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Injectable contraception: the USA perspective.
    Kaunitz AM
    IPPF Med Bull; 1992 Dec; 26(6):1-3. PubMed ID: 12346920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand.
    Pardthaisong T; Gray RH; McDaniel EB
    Lancet; 1980 Mar; 1(8167):509-12. PubMed ID: 6102234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?
    Rosenfield A; Maine D; Rochat R; Shelton J; Hatcher RA
    JAMA; 1983 Jun; 249(21):2922-8. PubMed ID: 6221125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adolescent satisfaction with postpartum contraception and body weight concerns.
    Hellerstedt WL; Story M
    J Adolesc Health; 1998 Jun; 22(6):446-52. PubMed ID: 9627814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
    Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
    Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depo-Provera: just another contraceptive?
    Jones M
    Fertil Contracept; 1978 Apr; 2(2):26-9. PubMed ID: 12336094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function.
    Petta CA; Faúndes A; Dunson TR; Ramos M; DeLucio M; Faúndes D; Bahamondes L
    Fertil Steril; 1998 Nov; 70(5):817-20. PubMed ID: 9806559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation.
    Pardthaisong T; Yenchit C; Gray R
    Contraception; 1992 Apr; 45(4):313-24. PubMed ID: 1387602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA gives final approval to Depo amid concerns over safety, cost and coercion.
    Wash Memo Alan Guttmacher Inst; 1992 Nov; (17):2-3. PubMed ID: 12344620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.